Renaissance Technologies
EWTX icon

Renaissance Technologies’s Edgewise Therapeutics EWTX Stock Holding History

Renaissance Technologies’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,465
Closed -$733K – 3670
2024
Q3 		$733K Buy
+27,465
New +$546K ﹤0.01% 2610
2024
Q2 		– Sell
-45,400
Closed -$828K – 3624
2024
Q1 		$828K Sell
45,400
-19,300
-30% -$307K ﹤0.01% 2597
2023
Q4 		$708K Sell
64,700
-86,300
-57% -$606K ﹤0.01% 2594
2023
Q3 		$865K Buy
151,000
+43,500
+40% +$296K ﹤0.01% 2401
2023
Q2 		$833K Buy
107,500
+10,700
+11% +$90.2K ﹤0.01% 2577
2023
Q1 		$646K Buy
96,800
+19,200
+25% +$178K ﹤0.01% 2735
2022
Q4 		$694K Buy
77,600
+19,300
+33% +$181K ﹤0.01% 2747
2022
Q3 		$574K Buy
58,300
+25,700
+79% +$260K ﹤0.01% 2846
2022
Q2 		$259K Buy
+32,600
New +$246K ﹤0.01% 3530

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies's EWTX Position: Q4 2024 in Review

Renaissance Technologies sold out of Edgewise Therapeutics (EWTX) in Q4 2024, closing a stake of 27,465 shares — an estimated $733K sold.

Renaissance Technologies first reported a position in EWTX in Q2 2022 and held it in 9 quarters. The position peaked at $865K in Q3 2023. 200 funds tracked by Wall St. Rank hold EWTX as of Q4 2024.

  • Renaissance Technologies reported no remaining Edgewise Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Renaissance Technologies sold 27,465 Edgewise Therapeutics shares in Q4 2024, an estimated $733K.
  • Renaissance Technologies first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 9 quarters.
  • Renaissance Technologies's Edgewise Therapeutics position peaked at $865K in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.